Last reviewed · How we verify
KDR2-2
At a glance
| Generic name | KDR2-2 |
|---|---|
| Also known as | KDR2-2 suspension eyedrop, KDR2-2 ophthalmic suspension |
| Sponsor | Guangzhou HuiBoRui Biological Pharmaceutical Technology Co. Ltd |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- KDR2-2 Suspension Eyedrop in the Treatment of Neovascular Glaucoma (KDR-NVG) Trial (PHASE1)
- The Safety and Efficacy of KDR2-2 Suspension Eye Drops in the Treatment of Corneal Neovascularization (PHASE1, PHASE2)
- Clinical Evaluation of Safety and Tolerability of KDR2-2 Eye Drops in Healthy Volunteers With Pharmacokinetic Assessment (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- KDR2-2 CI brief — competitive landscape report
- KDR2-2 updates RSS · CI watch RSS
- Guangzhou HuiBoRui Biological Pharmaceutical Technology Co. Ltd portfolio CI